Podcasts about natural killer

St. Louis researchers are participating in a larger study of children and young adults with recurrent brain tumors.  The trial will test a promising type of immunotherapy using Natural Killer -- or N-K cells -- a type of immune cell that can recognize and kill cancer cells while sparing healthy cells.The research is being supported by a two-million-dollar grant from CureSearch for Children's CancerKMOX's Megan Lynch gets mre from Dr. Mohamed Abdelbaki Associate Professor of Pediatrics at Washington University School of Medicine in St. Louis, Missouri. He also serves as the Director of both the Pediatric Neuro Oncology Program and the Clinical Research Office (CRO) for the Pediatric Hematology, Oncology and Bone Marrow Transplant Division at St. Louis Children's Hospital. 

GUEST BIO Paul Y. Song is an MD, entrepreneur and health activist. He is currently CEO of NKGen Biotech. Dr. Song served as the very first visiting fellow on healthcare policy in the California Department of Insurance in 2013. His last clinical role was Asst. Professor at the Samuel Oschin Cancer Center at Cedars Sinai Medical Center. He currently serves on several boards including: the Pritzker School of Molecular Engineering at the University of Chicago Mercy Corps, The Center for Health and Democracy, Gideon's Promise, and Progressive Democrats of America. Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. He completed his residency in radiation oncology at the University of Chicago.. Instagram DEFINITIONS Single-payer healthcare: A type of universal healthcare in which the costs of essential healthcare for all residents are covered by a single public system (hence "single-payer"). Single-payer systems may contract for healthcare services from private organizations (as is the case in Canada) or may own and employ healthcare resources and personnel (as is the case in the United Kingdom). Medicare: A government national health insurance program in the United States. It primarily provides health insurance for Americans aged 65 and older, as well as for disabled people. MENTIONED Natural Killer Cells - Alzheimer's Clinical Trials Physicians for a National Health Program Courage CA TAKEAWAYS Alliances are powerful. Finding common goals across movements can amplify each of their individual causes more effectively. A single payer system isn't just better for patients, but also for doctors, who won't have to spend resources fighting insurance companies, or worrying about malpractice insurance. In reality, US patients are not really free to choose their providers. Most of the time, the insurance provider is the one dictating who you have access to, and what medication you're allowed to take under their coverage. As long as our politicians remain beholden to the insurance lobby, we will not get universal healthcare. A new therapy using the patient's own natural killer cells may be the key for Alzheimers, Parkinsons and Cancer patients. CONTACT Instagram | TikTok | Web | LinkedIn | Twitter Host: Lazou --- Send in a voice message: https://podcasters.spotify.com/pod/show/nuancespod/message Support this podcast: https://podcasters.spotify.com/pod/show/nuancespod/support

A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer's disease, with remarkable results.This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer's treatment landscape.00:58-02:55: About NKGen Biotech 02:56-05:39: Why is Alzheimer's so challenging to treat? 05:39-07:28: Are there other treatments making a difference? 07:28-13:47: What is NKGen Biotech's approach to treating Alzheimer's? 13:47-15:38: Can you treat multiple conditions at the same time? 15:38-15:55: Are there any side effects? 15:55-16:33: What dose are you able to give? 16:33-18:31: How can you keep the cost of treatments low? 18:31-19:19: How, and how often, will it be administered? 19:19-20:49: How are you approaching taking on later stage Alzheimer's? 20:49-22:21: Are you looking to cure Alzheimer's? 22:21-23:50: Can this approach be used for other diseases? 23:50-24:47: Are you looking for partnerships? 24:47-25:47: What stage are your trials at? 25:47-26-19: What are the next steps for NKGen Biotech? 26:19-26:35: How are you enrolling patients? 26:35-27:32: What is your approximate timeline?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

On this week's Tech Nation, Moira speaks with Dr. Robert Ang, the President & CEO of Vor Biopharma, about its approach to Acute Myeloid Leukemia, also known as AML. Then, Dr. Nik Sopko, the chief scientific officer of PolarityTE, talked about their design for wound healing. Their first treatment candidate is diabetic foot ulcers, and Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

Alert: A Must Hear. New COVID Variant Very Deadly to Vaccinated. Prepare Now. Buy Ivermectin, Hydroxychloroquine, etc. Now.   To watch the entire 1:37 minute interview visit- https://www.youtube.com/live/EoMH2R0vVxM?si=9qrW6pdyUYNKTl1I Geert's Concern about the New Covid Variant (JN.1) Vejon Health 95.6K subscribers 83,098 views Streamed live on Dec 21, 2023 #CovidVaccines #COVID19 #covid Dr. Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer. He then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager and subsequently joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. Geert is now primarily serving as a Biotech/Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines. Website: https://www.voiceforscienceandsolidar...  Latest news, research and updates about COVID-19 and health. Join on Substack: https://philipmcmillan.substack.com/ Join on Patreon:   / vejonhealth   #COVID19 #CovidVaccines FREE and Paid Courses Available! https://mcmillanresearch.com/mr-educa... Watch videos at McMillan Research: https://mcmillanresearch.com/media/ #covid #medicine #research Transcript available at: https://www.youtube.com/live/EoMH2R0vVxM?si=9qrW6pdyUYNKTl1I

Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, shedding light on the capital-intensive nature of drug development. Furthermore, he highlights the value of experienced investors and the impact of their investment source, emphasizing the advantage of being one of the first investments out of a fund. Knowles also provides an update on Affini-T Therapeutics' focus on developing therapies for solid tumors, offering a glimpse into their innovative approach using cell therapy and synthetic biology to address the challenges of the tumor microenvironment. His journey and expertise in navigating the intricacies of fundraising and company-building make this episode essential listening for entrepreneurs in the biotech industry, providing practical lessons and strategic insights for overcoming funding obstacles and driving success in the competitive landscape of biotechnology.,In this episode of the Biotech2050 podcast, Jak Knowles, the co-founder of Affini-T Therapeutics, offers valuable perspectives on the challenges encountered by bootstrapped biotech companies and the pivotal role of venture capital in the industry. Knowles emphasizes the significance of early intellectual property acquisition and strategic partnerships as critical factors in the capital-intensive arena of drug development. Furthermore, he underscores the importance of securing investment from experienced sources and elaborates on the benefits of being an early investment in a fund. Knowles also provides an update on Affini-T Therapeutics' focus on developing innovative therapies for solid tumors, showcasing the company's pioneering approach involving cell therapy and synthetic biology to address the complexities of the tumor microenvironment. With his wealth of experience and expertise, Knowles offers essential insights for biotech entrepreneurs, providing actionable strategies and valuable lessons for navigating the funding landscape and achieving success in the competitive biotechnology sector. Biography: Jak Knowles, MD, is Co-Founder, President and Chief Executive Officer of Affini-T Therapeutics. He has more than two decades of R&D, management, and entrepreneurial experience in the life science industry. Prior to launching Affini-T, Jak served as Co-founder and Chief Business Officer for Metagenomi, a next-generation gene editing company based in Berkeley, California. Jak was previously Head of Pharma Venture Investments for Leaps by Bayer, where he helped lead Metagenomi's initial seed financing and early strategy serving on Metagenomi's Board of Directors. Before joining Bayer, Jak served as Chief Executive Officer of CytoSen Therapeutics, where he developed Natural Killer immune cell therapies for oncology indications. In 2016, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company, serving as President and interim-Chief Executive Officer. Jak previously served on the Board of Directors for Century Therapeutics, Exonics Therapeutics, Metagenomi Technologies, Triumvira Immunologics, and Pyxis Oncology. Jak earned his MD from Stanford University where he graduated with honors in biomedical research, and an undergraduate degree in biology from Binghamton University

References Anal Cell Pathol (Amst).2018; 2018: 787.1814 Zeno (the Eleatic) 5thCentury B.C. Magna Graecia, Italian Penn. Student of Parmenides Guerra-basic immunology lectures Schubert,F. 1826.String Quartet No. 15 in G major, D. 887. https://youtu.be/xW8PI2Xa8eA?si=smnLmSKamUP34qon --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

This week, we speak to Artiva Biotherapeutics' CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company's cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles.Artiva's pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. 

Drs. Lillian Siu and Melvin Chua discuss scientific innovations, disruptive technologies, and novel ways to practice oncology that were featured at the 2023 ASCO Breakthrough meeting in Yokohama, Japan, including CRISPR and gene editing, CAR T-cell and adoptive cell therapies, as well as emerging AI applications that are poised to revolutionize cancer care.   TRANSCRIPT Dr. Melvin Chua: Hello, I'm Dr. Melvin Chua, your guest host of the ASCO Daily News Podcast today. I'm a radiation oncologist and I currently practice in the Division of Radiation Oncology at the National Cancer Center in Singapore. I also served as the chair-elect of the ASCO Breakthrough Program Committee, and, on today's episode, we'll be discussing key takeaways from this year's Breakthrough meeting. The global meeting in Yokohama, Japan, brought together world-renowned experts, clinicians, med-tech, pioneers, and novel drug developers to discuss scientific innovations and disruptive technologies that are transforming cancer care today. I'm joined by Dr. Lillian Siu, the chair of the Breakthrough Program Committee. Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a professor of medicine at the University of Toronto.     You'll find our full disclosures in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod.    Lillian, it's great to be speaking with you today.    Dr. Lillian Siu: Thanks, Dr. Chua. I'm happy to be here.    Dr. Melvin Chua: We were just at ASCO Breakthrough, and it showcased some incredible scientific innovations, and really showed us how technology innovations in precision oncology, biotech, and artificial intelligence are transforming cancer care. What are your thoughts?    Dr. Lillian Siu: Yeah, it was a really exciting meeting, Melvin. The theme of this year's Breakthrough meeting was “Shining a Light on Advances in Cancer Care.” And our Opening Session featured an illuminating keynote address by the renowned thought leader and tech trailblazer, Dr. Hiroshi or “Mickey” Mikitani, the founder and CEO of Rakuten and Rakuten Medical. In his address that was titled, “Innovative Technology and Oncology,” he spoke so passionately about innovation and really seeing around the corner to predict what is coming and taking risks. And I think that's what medicine is about, not just what we have in front of us, but to predict and forecast what's coming. I totally was inspired by his address, and I think a lot of the audience felt the same way. He also spoke to us a bit about his company's development in photoimmunotherapy using novel technology and light therapy in head and neck cancer. And I think that's also an area of new technology that we should watch in the next few years.    Dr. Melvin Chua: I totally agree with you, Lillian. And one of the quotes that he spoke about really spoke to my heart. He spoke about the 2 choices: whether to do or not to do and not to do is not an option. So, I think that was a very compelling message to a lot of our audience at the meeting.    So, on this same note, innovation is a driving force in oncology, and we saw countless examples of this throughout the Breakthrough meeting. Were there any sessions that really stood out for you?    Dr. Lillian Siu: There were so many exciting sessions. First of all, there is the “Drugging the Undruggable” session. This is a really important session because in the past we felt that certain cancer targets such as KRAS, MYC, etc., are not druggable. KRAS G12C is the poster child in this area. So, during this session we heard about many ways that we are now looking to target these so-called undruggable molecules in the cancer cell. And we talked about molecular glues, we talked about degraders, and really novel ways that are not yet reaching the clinic, called “cyclic peptides” were discussed by one of the speakers.     The other session that is very interesting also is CRISPR and gene editing. Obviously, we all know a little bit about gene editing, really trying to change or knock in some genes that are important perhaps to change the function. And one of the sessions talked about trail targeted induced mesenchymal stem cells, and perhaps this is a way to, again, deliver novel therapies and novel treatments to our patients. There were many examples of how CRISPR and gene editing can be ultimately going to the clinic to benefit our patients in terms of therapeutics.     I want to highlight another session, which is the CAR T-cell and Adoptive Cell Therapies. I think everybody knows about CAR T-cells, but in this session we talk about non CAR T-cells or newer things such as off the shelf NK cells, Natural Killer cells from cord blood. So, this way it is allogeneics, in other words, we don't have to rely on only a patient's donation of their samples, but actually get it from off the shelf from other donors. There are other ways to really use human induced pluripotent stem cells that we can armor them by transgenes and also CRISPR out any unwanted genes, for example, to enhance an effective function of T-cells. So many, many exciting ways to bring these cell therapies to the patients.     And last but not least, I want to highlight Dr. Chris Abbosh, who is one of our keynote speakers, talking about molecular and minimal residual disease and early cancer detection using circulating tumor DNA or liquid biopsy. He talked passionately about the TRACERx study, which he is instrumental in terms of leading together with Charlie Swanson in the UK. This is a study that really has uncovered a lot of science about cancer heterogeneity. And in that study, he also studied circulating tumor DNA and really shed a lot of light about clonal and subclonal dynamics over time that changes.     Dr. Melvin Chua: And just to touch on that point about innovation and how that translates to cancer care, I think it was great that we had those case-based applications in lung cancer, in breast cancer, and the virus-associated cancers. And I like how the speakers were able to bring in the Ying and the Yang, bring the West and the Eastern perspectives in these interactive sessions. I particularly enjoyed all of them. But the session on the lung case discussion where we know that there were this EGFR mutant lung cancers that are prevalent in this part of the world in Asia. I thought the interaction between the speakers was fantastic.     On the same note about therapies and we heard about novel therapeutics at this meeting as well. I wonder what your thoughts are about some of the sessions, and do you think some of these technologies were able to be brought into practice? And your thoughts on the novel therapeutic session that happened at Breakthrough, do you think this will actually impact clinical care?    Dr. Lillian Siu: Oh, for sure, Melvin. The 5 areas that were covered during the Novel Therapeutics session are really drugs already in the clinic. And for example, the first one was about antibody drug conjugates. We know there are now at least 12 antibody drug conjugates already approved by the FDA and many more likely to be approved in the near future. And the session really talked about what's next, how to improve upon ADC, for example, using better drug antibody ratio, talking about new payloads and really new formats that make perhaps ADCs even more potent in the future.     There was a session on oral immunotherapeutics. It was really how to target the innate immunity. And I think novel oral immunotherapeutics is very important because we all know PD-1, PD-L1 inhibitors have been the backbone, but we need another Breakthrough. And having oral immunotherapeutics will make it very attractive for patients because they don't have to come to the cancer center to receive the drugs.     Another part of that session was about T-cell engagers and bispecifics, really how to bring molecules to the T-cell, to the effective cells so that they are able to be phytotoxic to the tumor. We talked about also oncolytic viruses, how are the new ways to utilize this kind of natural agent to target the cancer cells. And lastly, we also talked about personalized cancer vaccine, which is obviously very timely. We all know a lot about vaccine now after the COVID pandemic and how do we use cancer vaccines to be a good therapeutic drug? I think especially important in the earlier disease stages as adjuvant therapy. Some exciting data, for example, in pancreatic cancer, as adjuvant really is groundbreaking for this whole topic of cancer vaccination.    Dr. Melvin Chua: That's great. And for me as a radiation oncologist who's not so deep in drug development, hearing all the talks at ASCO Breakthrough was really informative for me and I learned a lot. In particular, you spoke about the whole session there was oncolytic therapy and the results in glioblastoma multiforme, we know it's a deadly disease, was certainly very impressive. And so, it speaks to the whole notion that in fact, some of this stuff is in fact reaching the clinic and making a difference in deadly diseases. I think there's a lot to take in from there.    Dr. Lillian Siu: Melvin, you're so humble. I know you're a big expert in artificial intelligence and I think the whole session about AI applications in precision medicine really was not just in that session, but a whole theme that went throughout the entire meeting. So, I'm very interested to know what you think about some of the presentations around AI and disruptive technologies in precision medicine, such as next-generation multiomics, etc. What are your thoughts?    Dr. Melvin Chua: Absolutely, I agree with you. And there was so much material within the AI session, the multiomic session, as well as the keynote [address] by Dr. Maryellen Giger, which basically speaks about some of the pre-existing or historical work on artificial intelligence in radiology. And I'd like to first talk about the keynote by Dr. Maryellen Giger. It was very nice that she elegantly showed how AI was in fact already in practice in radiology, where it helped to fulfill or address a need for radiologists. Almost 20 years ago, they were able to show that using computer vision, you were able to basically facilitate the calling of abnormal mammograms. And it was inspiring to see how these early thoughts have now basically accelerated a lot of the advances that we see that are in practice today.     The other thing that was also was to see this global collaboration, the need for global collaboration in the artificial intelligence space and the radiologists are clearly leading the way. And I think part of the impetus for this effort came from an opportunity that arose during the COVID pandemic that clearly affected all facets of healthcare. That was a nice segue to the very sort of dense 1 hour session we had on precision oncology care with artificial intelligence. I think when we designed this session, we were very deliberate that we wanted to address all aspects of how AI could be applied. From real-world clinical data, we saw examples of how having good, well-annotated data sets could actually help to accelerate and facilitate liver cancer screening in Hong Kong. Then we also saw a very simple, practical application of AI in pathology, where apart from just having this tool to be able to extract features that could potentially predict outcomes of patients and predict drug responses, we saw a very practical example that applying AI in digital pathology could actually homogenize or harmonize the ways the pathologists review their cases. And so, I thought that was very neat and could speak to all our clinicians across both developed and developing countries.     We also saw very exciting stuff on the use of AI in terms of calling out mutations because we know that next-generation sequencing is pretty much a cornerstone of how we practice in oncology today. And yet we know that there are prohibitive costs that preclude this technology in certain parts of the world. And it was nice to see how AI could actually lower the cost of some of these sequencing technologies like being used in liquid biopsy.     And then finally, there was some fancy science as well that was showcased in the spectrum when we saw how industry as well as academics are thinking about integrating multiomic data sets to then be able to accelerate drug discovery, help define patients better, and so that we can think about how to look at precision oncology using targeted treatments for specific patient phenotypes. So I think this was a very nice transition to the Next-Generation Multiomic Technology session, where, again, some of these topics were touched on, ranging from liquid biopsies, and this was already covered in Dr. Abbosh's talk, which you spoke about, and as well as the preceding day session where we heard snippets of it. And it was again reinforced by the speakers when it showcased liquid biopsies. We have heard so much about it in the last decade and we see it made approved now for use in the clinic, but yet so much remains unknown, like the discrepancies between assays, addressing the cost of assays and, importantly, how we deal with the information. So, I think we are just at the tip of the iceberg here. A lot of the clinical evidence needs to be generated in due course to address some of these questions.     At the same time, it was also nice to see some of the new technologies being applied in discovery science. So, we know that immunotherapy is a major player in oncology today, and the Breakthrough represents a forum whereby we're able to bring translational scientists to showcase their work. And we saw examples of that at this meeting where single cell technology, digital spatial technology, being able to apply that in pathology specimens and how the two are integrated to be able to review more novel science to us, to show us how immunotherapy works or doesn't work in some patients. Both of us have touched on so much content that was showcased at the Breakthrough, and I think this speaks to the impact, the learning experience we've had from Breakthrough and I think that's the intended purpose of this meeting.    Dr. Lillian Siu: Yeah, I agree. It truly was a very exciting 3 days. And I particularly like the multiomics session where we see that the technology is so advanced just in a really short period of time. Over the last few years, we've been now able to go into single cell resolution where in the past I don't think we would ever dream of being able to do that. In fact, I recall in the single cell session, we can even see messenger RNA on the slide, which I thought was fascinating, something that I cannot imagine we can see by the naked eye. It really is an exciting time in oncology, Melvin, and the field is advancing with these new innovations and therapies, but at the same time, I think it's important that we do live globally and we need to work really also to help improve access to quality-assured cancer medicines and diagnostics in the low and middle income countries. What do you think about that part? Did we do a good job in addressing that in the meeting?    Dr. Melvin Chua: Absolutely, Lillian. We had a special session that was chaired by Dr. Peter Yu and the lecture was delivered by Dr. Gilberto Lopes from the University of Miami. And we know that he's a strong advocate for this. And the session title spoke to this topic very pointedly, “How Science, Technology, and Practice Can Be Enabled in Lower- and Middle-Resource Settings.” And I thought that the work that he highlighted, the whole ATOM coalition, was important. ATOM basically stands for Access to Oncology Medicines, and it was established last year by the UICC, the Union for International Cancer Control, along with global partners to improve access to anti-cancer drugs and to develop processes for ensuring quality delivery, as well as the optimal utilization of medicines in middle- and low-resource settings. And I think there's a lot more work to be done.     Some of the information they showed was very compelling to me from this part of the world. But we know that Asia isn't very heterogeneous in terms of the resources, in terms of the culture. And I thought that the drug pricing, for example, how that should be addressed across the different countries is an important topic to pick up. And I hope his lecture only invigorates this conversation going forward.     Dr. Lillian Siu: Yeah. Thanks, Melvin. I totally agree. That was very inspiring. Breakthrough is such a one of a kind, international gathering that we are not only able to network while we're there; we also have a session to really allow attendees to leverage international cancer networks, to learn a bit about them, all the way from, for example, some of the North American groups to Asia Pacific groups to even global groups, and how we interact between pharma and academia, really transcending boundaries. And I think it is really, really important for us to now have these networks address issues such as equity and cancer care innovation, novel approaches and so much more. And I think, I am sure you're going to do a good job in making sure that gets into the agenda in our next year's meeting in 2024. Ultimately, we hope that these collaborations in cancer research will help to improve the outcomes for our patients with cancer.    Dr. Melvin Chua: Thank you again for sharing the great highlights of ASCO Breakthrough, and I'm really appreciative of your work, and your commitment to build a really robust program for this year. So, thank you.    Dr. Lillian Siu: And thank you, Dr. Chua. And you can bet that I will not miss Breakthrough 2024 in Yokohama in August next year. I will be there.    Dr. Melvin Chua: Okay, I'll hold you to that.     And thank you to our listeners for your time today. You'll find links to all of the sessions discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you again.    Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Find out more about today's speakers: Dr. Lilian Siu  @lillian_siu  Dr. Melvin Chua  @DrMLChua    Follow ASCO on social media:   @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. Lillian Siu:  Leadership (Immediate family member): Treadwell Therapeutics  Stock and Other Ownership Interests (Immediate family member): Agios    Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen    Dr. Melvin Chua:  Leadership, Stock and Other Ownership Interests: Digital Life Line  Honoraria: Janssen Oncology, Varian  Consulting or Advisory Role: Janssen Oncology, Merck Sharp & Dohme, ImmunoSCAPE, Telix Pharmaceuticals, IQVIA, BeiGene  Speakers' Bureau: AstraZeneca, Bayer, Pfizer, Janssen   Research Funding: PVmed, Decipher Biosciences, EVYD Technology, MVision, BeiGene, EVYD Technology, MVision, BeiGene  Patents, Royalties, Other Intellectual Property: High Sensitivity Lateral Flow Immunoassay for Detection of Analyte in Samples (10202107837T), Singapore. (Danny Jian Hang Tng, Chua Lee Kiang Melvin, Zhang Yong, Jenny Low, Ooi Eng Eong, Soo Khee Chee)       

Dr. Paulo Garcia, CEO and Co-Founder of Kytopen, is developing systems to refine the types of payloads, including RNA, DNA, and CRISPR-Cas RMP, that can be delivered to primary T cells, primary Natural Killer cells, and CD34 stem cells. To maximize the number of successfully engineered cells, the Flowfect Discovery technology, using a non-viral approach, automates the process of cell engineering and gene delivery into cells while dramatically reducing the time to produce the cells. Paulo explains, "One of the key differentiating aspects of our technology is that we are using a continuous fluid flow format for the engineering of our cells. This fluid flow contributes to the delivery of these payloads to the different cells. And to put it into perspective, the flow rates that we use are quite large. They are in the tens of milliliters per minute. And if you translate that into a throughput of cells, you're talking about being able to process anywhere between 1 to 2 billion cells in 30 seconds. And these are large quantities of cells that have the possibility of being able to be then used not only in an autologous setting but also in an allogeneic setting in which many cells have to be administered to the patients in the different doses that are required." "No technology currently processes at the high-volume rates we're talking about. And generally, what is done today is a batch process. There are non-viral techniques, and there are viral techniques, but what is required is for these cells to be introduced into a bioreactor divide, let them grow to the relevant numbers, and then they can be administered to the patients. And with a process that leverages the throughput of the Flowfect technology that Kytopen is developing, you can really reduce the time these processes take. And that is the vein-to-vein time, and reduce it to numbers that are measured in days as opposed to in weeks or months." "Right now, our goal is to shrink the time that it takes from discovery to process development and into clinical manufacturing with the Flowfect technology that leverages different types of energy, mechanical energy, electrical energy, and buffer chemistry to give the best outcome and chance of the cells to be engineered and modified for the therapeutic applications of our partners." #Kytopen #CellTherapy #ClinicalManufacturing #CellEngineering Kytopen.com Download the transcript here

Dr. Paulo Garcia, CEO and Co-Founder of Kytopen, is developing systems to refine the types of payloads, including RNA, DNA, and CRISPR-Cas RMP, that can be delivered to primary T cells, primary Natural Killer cells, and CD34 stem cells. To maximize the number of successfully engineered cells, the Flowfect Discovery technology, using a non-viral approach, automates the process of cell engineering and gene delivery into cells while dramatically reducing the time to produce the cells. Paulo explains, "One of the key differentiating aspects of our technology is that we are using a continuous fluid flow format for the engineering of our cells. This fluid flow contributes to the delivery of these payloads to the different cells. And to put it into perspective, the flow rates that we use are quite large. They are in the tens of milliliters per minute. And if you translate that into a throughput of cells, you're talking about being able to process anywhere between 1 to 2 billion cells in 30 seconds. And these are large quantities of cells that have the possibility of being able to be then used not only in an autologous setting but also in an allogeneic setting in which many cells have to be administered to the patients in the different doses that are required." "No technology currently processes at the high-volume rates we're talking about. And generally, what is done today is a batch process. There are non-viral techniques, and there are viral techniques, but what is required is for these cells to be introduced into a bioreactor divide, let them grow to the relevant numbers, and then they can be administered to the patients. And with a process that leverages the throughput of the Flowfect technology that Kytopen is developing, you can really reduce the time these processes take. And that is the vein-to-vein time, and reduce it to numbers that are measured in days as opposed to in weeks or months." "Right now, our goal is to shrink the time that it takes from discovery to process development and into clinical manufacturing with the Flowfect technology that leverages different types of energy, mechanical energy, electrical energy, and buffer chemistry to give the best outcome and chance of the cells to be engineered and modified for the therapeutic applications of our partners." #Kytopen #CellTherapy #ClinicalManufacturing #CellEngineering Kytopen.com Listen to the podcast here

Visiting a forest can induce a significant increase in both the number and activity of natural killer cells, one of the ways our body fights off cancer.  Can the aroma of wood essential oils replicate the immune-boosting effects of walking in a forest?

Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer, he then worked with the Global Alliance for Vaccines and Immunization (GAVI) ============================== Please Consider Donating so I may Continue to Create FREE Content https://www.awakeningpodcast.org/support/ ========================================== Freedom Broadcaster Livestream On April 27, 2023 Grace from Start to 26:55 & 1:05 to finish Roy From 26:55 to 49:50 Jayne from 49:50 to 1:05 Guest: Dr. Geert Vanden Bossche Topic:  The Inescapable Immune Escape PandemicBook: The Inescapable Immune Escape Pandemic Bio: Dr. Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager and subsequently joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. Geert is now primarily serving as a Biotech/ Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines. As a creative thinker, innovator, entrepreneur and visionary, Geert has been invited to speak at multiple international congresses. His work and supportive advice are driven by a relentless passion to translate scientific breakthrough findings into competitive solutions to emerging challenges in public and global health. Dr. Vanden Bossche has become world famous for warning Humanity against the health danger of conducting mass vaccination programs during a pandemic (March 2021). What we Discussed: - How is his family and circle of friends regarding the jab - What is a Natural Pandemic - Innate immunity - None of the measure that the authorities introduced make sense - Does he know that the Gates foundation and WHO know that Vaccines don't work - The WHO depends on Sponsors and its problems - Why were Dr's and Hospitals Incentivised to put patients on ventilators - Studies prove that the measures were wrong to lockdown and mask - I (Roy) do not believe any vaccine work with all the toxins - Natural things to build your immunity - Why the Vaccines should stop - How critical mass can make change - Hes against the yearly flu vaccine - Children should not be getting so many vaccine's at a young age and more Interview Panel Grace Asagra, RN MA (Holistic Nurse, US, originally from the Phil)Podcast:  Quantum Nurse: Out of the Rabbit Hole from Stress to Bless⁠ www.quantumnurse.life⁠ TIP/DONATE LINK for Grace Asagra  @ Quantum Nurse Podcast https://patron.podbean.com/QuantumNurse Dr. Jayne Marquis, ND Podcast: INpowered https://linktr.ee/INpoweredhealth Roy Coughlan Podcast: AWAKENING https://www.awakeningpodcast.org/ TIP/DONATE LINK for Roy Coughlan @ Awakening Podcast https://www.awakeningpodcast.org/support/ Dr. Geert Vanden Bossche : ⁠www.DrGeert.com⁠ ⁠http://substack.com/profile/57302394-geert-vanden-bossche⁠ Book https://www.amazon.com/Inescapable-Immune-Escape-Pandemic/dp/1956257691?asin=B0C1NZ16L1&revisionId=c516639f&format=1&depth=1⁠ More about Roy: All Podcasts + Coaching and Social Media https://bio.link/podcaster https://awakeningpodcast.org/ Donations  https://www.awakeningpodcast.org/support/ Video https://www.bitchute.com/channel/y2XWI0VCPVqX/ https://rumble.com/user/Awakening

Quantum Nurse www.quantumnurse.life presents Freedom International Livestream On April 27, 2023 Thursday @ 12:00 PM EST 5:00 PM UK 6:00 PM Germany Guest: Dr.Geert Vanden Bossche Topic:  The Inescapable Immune Escape Pandemic   www.DrGeert.com http://substack.com/profile/57302394-geert-vanden-bossche   Bio: Dr. Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager and subsequently joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. Geert is now primarily serving as a Biotech/ Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines. As a creative thinker, innovator, entrepreneur and visionary, Geert has been invited to speak at multiple international congresses. His work and supportive advice are driven by a relentless passion to translate scientific breakthrough findings into competitive solutions to emerging challenges in public and global health. Dr. Vanden Bossche has become world famous for warning Humanity against the health danger of conducting mass vaccination programs during a pandemic (March 2021).   Book: The Inescapable Immune Escape Pandemic https://www.amazon.com/Inescapable-Immune-Escape-Pandemic/dp/1956257691?asin=B0C1NZ16L1&revisionId=c516639f&format=1&depth=1                 Interview Panel   TIP/DONATE LINK for Grace Asagra  @ Quantum Nurse Podcast https://patron.podbean.com/QuantumNurse https://www.paypal.com/donate/?hosted_button_id=FHUXTQVAVJDPU               Grace Asagra, RN MA (Holistic Nurse, US, originally from the Phil) Podcast:  Quantum Nurse: Out of the Rabbit Hole from Stress to Bless www.quantumnurse.life Quantum Nurse - Bichute https://www.bitchute.com/channel/nDjE6Ciyg0ED/ Quantum Nurse – Apple https://podcasts.apple.com/us/podcast/quantum-nurse-out-of-the-rabbit-hole-from-stress-to-bliss/id1522579988 Quantum Nurse Earth Heroes TVhttp://www.earthheroestv.com/categories/the-freedom-broadcasters?via=grace Quantum Nurse Rumble https://rumble.com/c/c-764837 Quantum Nurse Podbean https://graceasagra.podbean.com       Dr. Jayne Marquis, ND  Podcast: INpowered  https://linktr.ee/INpoweredhealth   Roy Coughlan Podcast: AWAKENING https://www.awakeningpodcast.org/   TIP/DONATE LINK for Roy Coughlan @ Awakening Podcast https://www.awakeningpodcast.org/support/

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.17.537109v1?rss=1 Authors: Meza Guzman, L. G., Hyland, C. D., Bidgood, G. M., Leong, E., Shen, Z., Goh, W., Kratina, T., Rautela, J., Vince, J., Nicholson, S., Huntington, N. Abstract: The clinical development of Natural Killer (NK) cell-mediated immunotherapy marks a milestone in the development of new cancer therapies and has gained traction due to the intrinsic ability of the NK cell to target and kill tumour cells. To fully harness the tumour killing ability of NK cells, we need to improve NK cell persistence and overcome suppression of NK cell activation in the tumour microenvironment. The trans-membrane, protein tyrosine phosphatase CD45, regulates NK cell homeostasis, with genetic loss of CD45 in mice resulting in increased numbers of mature NK cells [1-3]. This suggests that CD45-deficient NK cells might display enhanced persistence following adoptive transfer. However, here we demonstrated that adoptive transfer of CD45-deficiency did not enhance NK cell persistence in mice, and instead, the homeostatic disturbance of NK cells in CD45-deficient mice stemmed from a developmental defect in the common lymphoid progenitor population. The enhanced maturation within the CD45-deficient NK cell compartment was intrinsic to the NK cell lineage, and independent of the developmental defect. CD45 is not a conventional immune checkpoint candidate, as systemic loss is detrimental to T and B cell development [4-6], compromising the adaptive immune system. Nonetheless, this study suggests that inhibition of CD45 in progenitor or stem cell populations may improve the yield of in vitro generated NK cells for adoptive therapy. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

 1:19 Labiotech.eu news2:32 Biomedical Research & Bio-Products12:15 Model N21:39 Institute of Clinical MedicineThis week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway; Kyle Forcier, senior director of life sciences product marketing at Model N; and Dr. Andreas Roetzer, head of R&D for vaccines at Biomedical Research & Bio-Products.The next breakthrough in cancer treatment?In our body, we have an innate immune system and an immune system that is developed throughout life. Part of the innate immune system consists of so-called NK (natural killer) cells. This is a type of immune cell that specializes in killing cancer cells. These cells may be of great importance for cancer treatment in the future. NK cells kill cancer cells with the help of small “killer torpedoes,” or vesicles, that the NK cells secrete. Vesicles are small bubbles with a fatty wall of lipids and a space filled with toxic proteins. Researchers at the Institute of Clinical Medicine in Norway have recently discovered new things about these killer vesicles.“We have discovered that we can separate the killer torpedoes from other types of vesicles so that they form a kind of arsenal of weapons. Our research also shows that this type of vesicle is probably stored in a separate room inside the NK cell,” Miriam Aarsund Larsen said.Model N publishes revenue reportModel N, Inc. recently announced the results of its fifth annual State of Revenue Report. The report captures detailed data intended to help life sciences and high-tech industry executives grappling with how to grow company revenue and market share. Most executives named inflation as a significant headwind, with 84% calling it the single biggest impact on innovation.“Our findings show three main themes: Innovation collides with current market realities, innovation directly impacts revenue management, and the use of technology for revenue management is expanding,” said Suresh Kannan, chief product officer, Model N. “As organizations continue to navigate the current economic climate, the quality and reliability of technology solutions are more important than ever. These insights help us understand how to empower our customers to create and bring life-changing products to market.”Phase 2 study of breakthrough vaccine against toxic shock syndrome successfully completedThe first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death.Nosocomial pathogen Methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely used antibiotics. Infections with MRSA are harder to treat and therapies are more expensive as the length of hospital stays is significantly prolonged. If the treatment does not lead to rapid clearance of the bacterial pathogen, dangerous symptoms such as septic or toxic shock can occur – a potentially life-threatening condition.Researchers at Biomedical Research & Bio-Products AG, under the direction of Martha Eibl, in cooperation with MedUni Vienna's Department of Clinical Pharmacology, conducted the study. The promising results showed the TSST-1 vaccine is safe and effective, with immunization lasting for at least two years. 

“This is the first time that I really felt what is meant by cell relations. You have object relations and you have part-object relations and anxieties that are depressive and schizophrenic. But when I deal with primitive anxieties, I really felt cell relations. What I felt is that my cells were going beyond my skin and I felt that she felt that my cells were going beyond her skin. You have this diffuse transference and when you have this sort of transference it took me to prenatal life and biological life.  Also, I had all those theoretical people like Tustin, Meltzer, and Bion - they were all talking about that.”      Episode Description: Shiri shares with us her journey from immunology to psychology to psychoanalysis. She brings her knowledge of immunologic processes to better grasp the internal mechanisms of the dynamic mind. She sees a relationship between the embryo's capacity to transform the mother's Natural Killer cells into a receptive matrix with later capacities for psychological maturation. We consider how this informed her work with a traumatized 4-year-old girl in a tumultuous analysis that demanded a great deal from each of them. We close with her sharing her vision for the future of psychoanalysis which hopefully will include ongoing collaboration with scientists from many disciplines.    Our Guest: Shiri Ben Bassat is a clinical psychologist and psychoanalyst with the Israel Psychoanalytic Society. She supervises at Franz Brill Mental Health Center (Ramat Chen, Tel Aviv) and teaches in various programs in the Studying Center of The Israel Psychoanalytic Institute. Shiri previously studied biology and holds an MA degree in immunology. She is the recipient of the 24th Frances Tustin Memorial Prize (2021).    Recommended Readings:  EPIGENETICS  Martin, S. (2014) R. Yehuda, N.P. Daskalakis, A. Lehrner, F. Desarnaud, H.N. Bader, I. Makotkine, J.D. Flory, L.M. Bierer, & M.J. Meaney (2014). Influences of maternal and paternal PTSD on epigenetic regulation of the glucocorticoid receptor gene in Holocaust survivor offspring. American Journal of Psychiatry 171:872-880.    Karla Ramirez , Rosa Fernández , Sarah Collet , Meltem Kiyar Enrique Delgado-Zayas , Esther Gómez-Gil , Tibbert Van Den Eynde , Guy T'Sjoen , Antonio Guillamon , Sven C Mueller , Eduardo Pásaro (2021) Epigenetics Is Implicated in the Basis of Gender Incongruence: An Epigenome-Wide Association Analysis. Front Neurosci Aug 19; 15:701017  PRIMITIVE ANXIETIES  Durban, J. (2019) "“Making a person”: Clinical considerations regarding the interpretation of anxieties in the analyses of children on the autisto-psychotic spectrum" The International Journal of Psychoanalysis 100:5, 921-939.  PRENATAL AND POSTNATAL  Meltzer, D. & Williams, M. H. (1988) 2. Aesthetic Conflict: It's Place in the Developmental Process. The Apprehension of Beauty: The Role of Aesthetic Conflict in Development, Art, and Violence 146:7-33  Bion, W. R. (1976) "On a quotation from Freud." In Clinical Seminars and Four Papers, Ed. F. Bion. Abingdon: Fleetwood Press, 1987.  Joanna Wilheim (2004) The trauma of conception. Presented at a Meeting of the Brazilian Society of Psychoanalysis of São Paulo (SBPSP) on October 7, 2004.  Trnsformation of the mother's immune system. Mandelboim, O. et al' (2006). Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nature Medicine 12: 1065 – 1074. 

Today, I am blessed to have here with me Dr. Gonzalez. He obtained his Ph. D and BS from the University of California, Irvine where he studied, and his thesis addressed interactions of the immune system following spinal cord injury. In addition to his expertise in degenerative disorders involving the spinal cord, he has extensive experience in stem cell culture and biology from various sources. He has extensive knowledge in all aspects of cell biology and health where he teaches worldwide on regenerative medicine and maintaining immune health. This episode originally aired in August 2021. Dr. Gonzalez is responsible for the development of clinical stem cell applications for several disease/trauma states. He leads 4 different investigational new drug applications with patented stem cell technology. Additionally, he works on the clinical development of immune based therapies using natural killer cells. He had led a reference laboratory in testing various regenerative medicine products. Dr Gonzalez has been in the regenerative medicine field for more than 18 years and has several scientific publications. He has taught, spoken and led many conferences nationwide in the regenerative medicine sector. In this episode, Dr. Gonzalez reveals the inspiration behind his career in the stem cell space. We speak about why cell therapeutics is known as the wild west and the amount of FDA testing Dr. Gonzalez goes through to ensure safe products. Then, Dr. Gonzalez dives into what exactly stem cells are and how they can improve the natural processes that are already occurring in your body. Tune in as we talk about the importance of fasting, turning your life around after an autoimmune diagnosis, and who should consider getting cell therapeutics. Order Keto Flex: http://www.ketoflexbook.com -------------------------------------------------------- / / E P I S O D E   S P ON S O R S  Dr Phillips CBD Oil & Keto Fruit Chews. Visit www.drphillipscbd.com Good Idea Functional Sparkling Water Drinks. Visit http://www.goodidea.us and use the coupon code BEN at checkout.  Text me the words "Podcast" +1 (786) 364-5002 to be added to my contacts list.  [00:45] Why Dr. Gonzalez Started In The Stem Cell Space At college, Dr. Gonzalez studied embryonic stem cell research in spinal cord injuries. He loves to understand and study cells. Stem cells have properties that can heal the body. Plus, Dr. Gonzalez believes that stem cells can work against aging. In fact, stem cells are made naturally inside our body. [08:00] The Wild West of Cell Therapeutics & FDA Testing Any form of cell therapeutics is like the wild west. When you submit for the cells to have a Chemical Manufacturing Composition, it takes years. Gonzalez got his first clinical study approved in 2019 with the FDA. Essentially, the FDA boils down to the amount of testing. They are always ensuring that the product is safe. [13:05] How Stem Cells Can Improve The Natural Processes In Your Body Pompa and Dr. Gonzalez have been looking at using stem cells to control the inflammatory state and increase blood flow. We need increased blood flow because you'll notice brain fog and a loss of energy without it. The natural property of our body is actually to increase blood flow any way that it can. The cells in your body have three fates: Natural cell turnover Necrosis Senescence When our cells stop dividing, they start occupying space and cause havoc. These cells can cause wrinkles and gray hair. There's a cell type in our body that is a natural killer. These cells have three jobs: Remove a cancer cell Pick up viral load Wipe out senescence cells If you don't have immune health, you essentially have nothing. Every single disease has an immune component to it. [22:10] The Critical Role Fasting Plays In Longevity Aging is an issue of cell growth. If you consume food incorrectly, your body has to process all that. When you keep dividing cells, you are causing senescence. One proven lifestyle change for longevity is fasting. Also, diet is important because you force your body to remove the toxins in your body.   [26:00] Transform Your Health With ReHealth's Cell Therapeutics Learn about ReHealth here: https://rehealth.com/ Register at the website, and they will contact you. The consultation is completely free. Depending on what you are looking to achieve will determine what type of therapeutics you should consider. Mesenchymal Stem Cell Therapy can help with the aging process. [30:30] How To Start Getting Your Life Back After An Autoimmune Diagnosis First and foremost, Dr. Gonzalez likes to discuss diet. If you are taking a bunch of meds, then you are not going to get better. Stem cells will give you a temporary effect unless you are doing all the key lifestyle components. Think about your goal. Gonzalez doesn't help people who are smoking. Stem cells will simply be a Band-Aid. Overall, stop smoking, start fasting, and fix your diet.   [33:00] How Frequently You Should Consider Working With ReHealth's Cell Therapeutics How often you will need cell therapeutics will depend on your goals and your situation. Some people will have one session and feel great for the next five or six years. Most people will get therapeutics every six months or every year. The effect of stem cells initially is far greater than the sequential effects. [42:30] The Type of Person That Should Seriously Consider Cell Therapeutics If you have immune issues, you need cell therapeutics. Also, if you've tried everything else, then you should try cell therapeutics. Sadly, doctors will want to hand you a pill. If you are going to go see someone, find someone who knows integrative medicine. If you have any questions, Dr. Gonzalez wants to answer them! Email: Rgonzalez@TheBioBox.com AND MUCH MORE! Resources from this episode: Check out ReHealth: https://rehealth.com/ Email: Rgonzalez@TheBioBox.com Follow ReHealth Instagram: https://www.instagram.com/rehealth.stemcells/ Facebook: https://www.facebook.com/rehealth.stemcells Twitter: https://twitter.com/Rehealth_ Join theKeto Kamp Academy: https://ketokampacademy.com/7-day-trial-a WatchKeto Kamp on YouTube: https://www.youtube.com/channel/UCUh_MOM621MvpW_HLtfkLyQ Order Keto Flex: http://www.ketoflexbook.com -------------------------------------------------------- / / E P I S O D E   S P ON S O R S  Dr Phillips CBD Oil & Keto Fruit Chews. Visit www.drphillipscbd.com Good Idea Functional Sparkling Water Drinks. Visit http://www.goodidea.us and use the coupon code BEN at checkout.  Text me the words "Podcast" +1 (786) 364-5002 to be added to my contacts list.  *Some Links Are Affiliates* // F O L L O W ▸ instagram | @thebenazadi | http://bit.ly/2B1NXKW ▸ facebook | /thebenazadi | http://bit.ly/2BVvvW6 ▸ twitter | @thebenazadi http://bit.ly/2USE0so ▸clubhouse | @thebenazadi Disclaimer: This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast including Ben Azadi disclaim responsibility from any possible adverse effects from the use of information contained herein. Opinions of guests are their own, and this podcast does not accept responsibility of statements made by guests. This podcast does not make any representations or warranties about guests qualifications or credibility. Individuals on this podcast may have a direct or non-direct interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.  

Key Takeaways:  How to outsmart cancer  Ways to create a body where cancer cannot thrive  The link between cancer risk and aging  Learn about the OUTSMART CANCER® System  Power super foods that can be targeted  Top supplements to taking  Episode Summary:  Integrative Cancer Answers is the fruit of Dr. Nalini Chilkov's thirty years of experience transforming the cancer journey for thousands of patients worldwide. Her OUTSMART CANCER® System offers plans that are recognized as the most comprehensive, safe and effective doctor-designed programs available today.  On my next YOUNGER podcast episode, you will meet my good friend Dr. Chilkov who will share her significant pathways to creating a body where cancer cannot thrive.  You will hear the answers to your Qs answered, such as:  What does “creating a body where cancer cannot thrive” really mean?  What is the link between aging and cancer?  How does your OutSmart Cancer System slow down and prevent the physiology of aging to contribute to the development of cancer? Guest Bio:   Dr. Nalini Chilkov is the Founder of IntegrativeCancerAnswers.com, the creator of the OUTSMART CANCER® System the author of the best-selling book, “Thirty-Two Ways to OutSmart Cancer: How to Create a Body in Which Cancer Cannot Thrive.”   Dr. Chilkov is a leading-edge authority on Integrative Cancer Care, Immune Enhancement, Optimal Nutrition and Wellness Medicine. Dr. Nalini's OutSmart Cancer Programs are recognized as the most comprehensive, science based, safe, natural programs for supporting cancer patients, cancer survivors and those who do not want to get cancer to Get Well, Stay Well and Live Well beyond cancer.   For over thirty years, Dr. Chilkov has helped thousands of people, many with serious and chronic illnesses, achieve and maintain extraordinary health and longevity and is sought out by Award Winning Hollywood celebrities and insiders.   Dr. Chilkov has been recognized and listed as a GO TO health care provider and clinician in Susanne Sommer's book, “Doctors Who Are Curing Cancer and How to Prevent Getting It in the First Place.”   Dr. Chilkov is one of the original Huffington Post's “Healthy Living Bloggers” and has appeared as a health expert on NBC TV, as well as, has been recognized by WebMD [sharecare.com] as one of the Top Ten Online Influencers in Breast Cancer.   Resources for a Younger Lifestyle:  Additional YOUNGER podcast episodes related to gut health: https://robynbenson.com/podcasts/   Episode #86: Demystifying Detox with Dr. Robyn Benson  Episode #25: Optimize Your Mitochondrial Health with Shawn Wells  Episode #20: Your Gut, Your Health, Your Wealth with Dr. Vincent Pedre  Episode #11: The Truth About Parasites in America with Dr. Glenn Wilcox  Episode #5: Your Health, Your Gut, Your Microbiome with Ken Brown, MD  Episode #2: Your Food, Your Health, Your Wealth with Terry Wahls, MD   Quotes:  “I find it disturbing to know when a cancer patient is in an oncology office, the word health rarely comes up in the conversation. This gives the patient a helpless feeling and can be interpreted that it isn't part of their goal for the patient.”  “Since I had direct experience with both parents diagnosed with cancer, I discovered what patients and families want the most which is to get their health back.  Once the doctor can accomplish this with the patient will not live in fear with the thought of cancer reoccurring again.”  “You can boost your immune system and increase Natural Killer cells.”  “Proactive cancer patients need to know there are specific herbs and supplements that are best used for EVERY STAGE of their cancer journey.”   

In this episode Phoebe from @sageandclare details her long journey to pregnancy and her two very different vaginal births. After close to three years of trying to conceive unsuccessfully, she was diagnosed with PCOS, endometriosis and Natural Killer (NK) cells. She began her IVF journey and fell pregnant on her second cycle but unfortunately, this coincided with ovarian hyperstimulation syndrome which took weeks to resolve. It was in her first pregnancy that she started experiencing severe hip pain and years later she was diagnosed with hip dysplasia, torn ligaments, arthritis and pelvic instability. She has made the conscious decision to grow her family before she has both hips replaced. 

This is one of the best of our Nature is the Cure episodes because it talks about the beneficial effects of nature when you inhale it! We all know how nostalgic smells can be. Any time you come across smells like brewing coffee or cookies baking in the oven it promotes memories and thoughts of positive moments in your past associated with those smells.Nature can has the same positive benefits and you most likely won't even know it's happening. A brief rundown of these benefits are reviewed in the episode and include...improved immune responses, especially with Natural Killer cells which can help fight against cancer and other diseasesanit-imflammatory benefits- specifically forest terpenes can reduce inflammatory stress on the bodyforest air can create a relaxation response on the body and reduce cortisol levelsphytoncides which are tree essential oils can enhance sleepIn fact the breathing in of nature has a higher positive effect than some of the other senses.Humans are also pretty remarkable when it comes to smelling Geosmin in the air as it comes from soil organisms and it can help us smell water. It is said that the human nose can pick up on 7 drops of geosmin in a swimming pool~ this definitely came in handy back in the early days.A quote from Florence Willliam's book states: The nose the direct pathway to the brain - small particulate air pollution causes lesions in the brain - “trees in the US remove 17.4 million tones of air pollution per year providing $6.8 billion dollars in human health benefits.” Check out Florence Williams' website HEREWe hope you enjoy this episode!!Thanks for your support of our podcast. Please leave a review or subscribe. Please email us with any questions, comments or suggestions...daring2dabblepodcast@gmail.comBe sure to check us out on Facebook and Instagram. Also please join our very new Facebook group... DARING TO DABBLE PODCAST COMMUNITYWe are super excited to connect with our listeners, let's all share our joy for trying new things and experiencing life to it's fullest.   MAKE LIFE FUN!!! Elise and Nicole are Intuitive Life Coaches, you can learn more about how they do what they do here:Elise Suronen website: https://mycoachelise.com/   Nicole Hope website: https://nhopeguidance.com/

On this week's Tech Nation, Moira speaks with the biotech companies at the BIO International Convention in San Diego. They meet in person for the first time in 3 years, where Dr. Gunn was able to speak with Paul Hastings, the Chair of BIO and the President & CEO of Nkarta, about the state of BIO and Nkarta's work on delivering Natural Killer cells for cancer. Joe Panetta, President & CEO of Biocom California, brings insights into California as a whole and its relation globally, as well as the price of drugs. Dr. Richard Austin, founder and CEO of Reglagene talks about choosing their first-in-human drug for the brain cancer, Glioblastoma, and Dr. Chris Nave from Brandon Capital describes Polyactiva's work in the treatment of glaucoma.

Companies in the biotech space are making contributions to help find a cure for cancer. Today's guest is no exception. In today's episode, Ammon Rivera sits down with Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they're using to develop a treatment for cancer. Daniel discusses how they've developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of disruptive innovation coming from the biotech industry. Daniel also discusses how the field is dealing with worsening market conditions amidst recent news of a special purpose acquisition with Isleworth Healthcare Corporation. There's much to learn from this episode, both in medicine and economics.

At 2000 deaths on an average per year, lightning kills more people than any other natural event or disaster. In this episode of Science & Us, we find out how climate change leads to an increase in lightning strikes, why it is not notified as a national disaster, and how we can protect ourselves from it. Our reporter Suryatapa Mukherjee speaks to Colonel Sanjay Srivastava, chairman of the climate resilient Observing System promotion Council (CROPC) and convenor of the Lightning Resilient India campaign. She also speaks to Arun Kundu, Secretary of Smart Future Foundation in West Bengal, about his work of visiting villages to make them lightning resilient. Our Contributing Editor Menaka Rao co-hosts this episode. Annual Lightning Report 2021-2022  Lightning occurrences and intensity over the Indian region: long-term trends and future projectionsProjected increase in lightning strikes in the United States due to global warming.Lightning kills more Indians than any other natural disaster. Can those deaths be prevented?See sunoindia.in/privacy-policy for privacy information.

On-Location Long Beach, CaliforniaOn this episode of Let's Be Blunt, Montel meets up with Tracy Ryan and Dr. Anahid Jewett at this year's Cannabis Science Conference. Tracy Ryan - a returning guest - has a daughter named Sophie who was diagnosed with a brain tumor at 8 1/2 months old (she's now 9 years old). Dr. Anahid is a respected immunologist and professor at UCLA School of Dentistry who has been studying natural killer cells for over thirty years. She has made numerous groundbreaking discoveries related to both cancer and ALS. Tracy connected with Dr. Jewett and they started treating Sophie as the first-ever natural killer cell treatment patient. If this treatment continues to be successful, it could become an incredible alternative treatment option for cancer patients.Support the show

On this week's Tech Nation, Moira speaks with Dr. Robert Ang, the President & CEO of Vor Biopharma about its approach to Acute Myeloid Leukemia, also known as AML. Then Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers. And Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

On this week's Tech Nation, Moira speaks with Dr. Robert Ang, the President & CEO of Vor Biopharma about its approach to Acute Myeloid Leukemia, also known as AML. Then Dr. Nik Sopko, the Chief Scientific Officer of PolarityTE talks about their design for wound healing. Their first treatment candidate is diabetic foot ulcers. And Dr. Eric Vivier from Innate Pharma in Marseilles tells us about the next wave of immunotherapy treatments – harnessing Natural Killer cells.

Truslow legit dropped his new album "Natural Killer" in RadioU's parking lot, then came in to join "The RIOT" morning show to chat it up!

Daniel Teper is the CEO and Founder of Cytovia Therapeutics and talks about using natural killer, NK, cells as an alternative to T-cells in immuno-oncology. He shares insights about the development of induced pluripotent stem cells, IPSC-derived NK cells, iNK cells, used by themselves or using their Flex-NK cell Engagers or in combination to address the challenges cancer patients face. Daniel elaborates, "That's also where the NK cells may have advantages over T-cells, in that it hasn't been reported that they cause CRS, GBHD, or other side effects that would require the patients to be kept in the hospital. Now, if we say the first iteration was derived from the patient's own blood, the second iteration is donor, the third generation, which we are one of a handful of companies to pursue and master, is the production of immune cells, including NK cells, from induced pluripotent stem cells." "We see also that you can direct the cells in two ways. You can direct the cells by inserting what's called a CAR, or chimeric antigen receptor, that's like a GPS on the cell. But alternatively, we can redirect the NK cells to kill the tumor cells by combining them with antibodies, and particularly with what we call NK engager antibodies. So our brand of NK engager antibodies is called Flex-NK cell engager antibodies. And what they do is that they have one arm that binds and activates the NK cell, and another arm that binds into the tumor cell, and the NK cells are redirected to kill the tumor cells." @Cytovia #CytoviaTX #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #CellTherapeutics #NKCells #iNKCells #NaturalKillerCells CytoviaTX.com Download the transcript here

Daniel Teper is the CEO and Founder of Cytovia Therapeutics and talks about using natural killer, NK, cells as an alternative to T-cells in immuno-oncology. He shares insights about the development of induced pluripotent stem cells, IPSC-derived NK cells, iNK cells, used by themselves or using their Flex-NK cell Engagers or in combination to address the challenges cancer patients face. Daniel elaborates, "That's also where the NK cells may have advantages over T-cells, in that it hasn't been reported that they cause CRS, GBHD, or other side effects that would require the patients to be kept in the hospital. Now, if we say the first iteration was derived from the patient's own blood, the second iteration is donor, the third generation, which we are one of a handful of companies to pursue and master, is the production of immune cells, including NK cells, from induced pluripotent stem cells." "We see also that you can direct the cells in two ways. You can direct the cells by inserting what's called a CAR, or chimeric antigen receptor, that's like a GPS on the cell. But alternatively, we can redirect the NK cells to kill the tumor cells by combining them with antibodies, and particularly with what we call NK engager antibodies. So our brand of NK engager antibodies is called Flex-NK cell engager antibodies. And what they do is that they have one arm that binds and activates the NK cell, and another arm that binds into the tumor cell, and the NK cells are redirected to kill the tumor cells." @Cytovia #CytoviaTX #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #CellTherapeutics #NKCells #iNKCells #NaturalKillerCells CytoviaTX.com Listen to the podcast here

While cancer immunotherapies have been promising, CAR T cell therapies have been costly, effective on less than half of patients, and focused on hematologic cancers. Cytovia Therapeutics is enlisting natural killer cells, part of the innate immune system, to develop off-the-shelf immunotherapies to treat liquid and solid tumors. The company is leveraging a cluster of technologies to produce CAR NK cell therapies, edited NK cells to enhance their targeting, and NK engagers to redirect NK cells toward tumor targets. We spoke to Daniel Teper, co-founder and CEO of Cytovia, about the case for NK immunotherapies, Cytovia's platform technologies, and the company's pipeline of therapies in preclinical development.

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness. Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines. https://www.voiceforscienceandsolidarity.org/scientific-blog/predictions-gvb-on-evolution-c-19-pandemic  https://twitter.com/GVDBossche  HELP ME CROWDFUND MY GAMESTOP BOOK. Go to https://wen-moon.com to join the crowdfunding campaign and pre-order To The Moon: The GameStop Saga! If you haven't already and you enjoyed this episode, please subscribe to this podcast and our mailing list, and don't forget, my book, Brexit: The Establishment Civil War, is now out, you'll find the links in the description below. You can listen to the show on Spotify - https://open.spotify.com/show/5AYWZh12d92D4PDASG4McB?si=5835f2cf172d47cd&nd=1  Apple Podcasts - https://podcasts.apple.com/us/podcast/chatter/id1273192590  Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5wb2RpYW50LmNvL2NoYXR0ZXIvcnNzLnhtbA  And all major podcast platforms.  Watch Us On Odysee.com - https://odysee.com/$/invite/@TheJist:4   Sign up and watch videos to earn crypto-currency!  Buy Brexit: The Establishment Civil War - https://amzn.to/39XXVjq  Mailing List - https://www.getrevue.co/profile/thejist  Twitter - https://twitter.com/Give_Me_TheJist  Website - https://thejist.co.uk/  Music from Just Jim – https://soundcloud.com/justjim 

Today I welcome back friend to the show, Dr. Rafael Gonzales. He's here to talk about regenerative medicine and using exosomes and natural killer cells to turn on cell communication. The post 407: Benefits of Natural Killer Cells appeared first on Dr. Pompa & Cellular Healing TV.

Today I welcome back friend to the show, Dr. Rafael Gonzales. He's here to talk about regenerative medicine and using exosomes and natural killer cells to turn on cell communication. The post 407: Benefits of Natural Killer Cells appeared first on Dr. Pompa & Cellular Healing TV.

Dr Dean Lee visits the studio as we consider natural killer (NK) cells. Learn how scientists genetically modify and grow these cells in the lab with the aim of helping kids fight cancer. We hope you can join us!

Select segments from PediaCast. For full-length episodes, visit PediaCast.org, Apple and Google Podcasts, iHeart Radio, Spotify, SoundCloud, Amazon Music or wherever else podcasts are found!

The allure of allogeneic “off-the-shelf” adaptive cell therapy (ACT) is obvious – by definition, the treatment is immediately available, and due to the nature of batch manufacture versus the one-off creations of an autologous ACT, it will very likely be cheaper. The question remaining is what cell type is best to use for clinical efficacy – T cells of the adaptive immune system, or natural killer (NK) cells of the innate system, OR, just maybe, a cell that does both – the CAR NKT cell therapy, from Athenex. Hear Dr. Daniel Lang, President of Athenex Cell Therapy, explain how this is possible.

Welcome to the next episode of the Personalized Medicine Podcast. On this podcast we have talked extensively about antibody, vaccine and CAR-T cell based approaches to treat cancer. Today we will be talking about a new approach in oncology that is based on invariant Natural Killer T Cells, or iNKTs. Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases. Together with Jennifer we discussed: ◦ Evolution of immunooncology over the the last two decades ◦ Role of immune system in fighting cancer ◦ Neoantigen vaccines as a tool for personalized cancer treatment ◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer ◦ Advantage of iNKTs over other cancer treatments ◦ Potential of combination therapies in oncology ◦ Challenges in bringing novel cell-based therapies to the market ◦ Advice to budding biotech entrepreneurs ◦ The outlook on the next decade of cancer treatmentGet in touch with Jennifer:LinkedIn: Jennifer S. BuellTwitter: @jbuell01Web: https://minktherapeutics.com/

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness. Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.

Today my guest is Pathologist Dr Vinay Kumar What we discuss with Dr Kumar: How his grandfather influenced him in becoming a doctor, and taught him the lesson of compassion How curiosity led him to study botany, and how it led him back to medicine How he became interested in research of disease mechanisms Traveling to the US to work with Dr Stanley Robbins in Boston, and some of his first experiences in the US His early research with Natural Killer cells Links for this episode: Health Podcast Network  LabVine Learning The ConfLab from LabVine Dress A Med scrubs   The Accidental Pathologist: A Curiosity-Driven Journey from Plant Evolution to Innate Immunity All India Institute of Medical Sciences Functions of Natural Killer Cells Robbins and Cotran Pathologic Basis of Disease   People of Pathology Podcast: Website Twitter

Today I'm with guest Dr Rahul Vangala This episode gets straight to the point in answering the grand question of “Why does a mother's immune system not reject a developing baby as foreign tissue?” Dr. Rahul Vangala's most interesting answer is compared to a person's rejection of organ transplants. He explains that along with the immune changes a mother experiences, the placenta's close knit anatomy is a certain immune privilege site that has the attributes of a nematode using neurokinines in order to remain “hidden” and not be detected by the host. If the host's body cannot recognize foreign substances, then it lacks the ability to enable defense mechanisms that would attack that foreign material. This is most favorable for a fetus and perpetuates gestation. He moves on to break down the complex immune responses our bodies have antigens, or foreign materials, by mentioning the main role of the TH1 T Helper Cell and it's critical function to rejecting organs. Dr. Vangala mentions this because during pregnancy it necessary that there be an ideal degree of immune suppression of TH1 responses by the presence of TH2 responses. Not only are TH1 cells suppressed but Natural Killer cells are also dampened. He then goes on to explain how the beginning stages of the placenta during implantation resembles a semi-allograft meaning that the tissues grafted in are only partially foreign. The two doctors then discuss a major topic of autoimmune disorders and the complications of attempting to get pregnant. They unveil the way the autoimmune diseases decrease the likelihood of an optimal environment for viable gestation. Although, it is not impossible for women who live with autoimmune disorders to get pregnant and deliver a health baby. However, all in all there are many adjustments to the mechanics in order to make what we see as precious miracles. #immunechanges #placenta #pregnancy #immunesystem #TCells #THelperCells #semiallograft #autoimmune #graft #host #Surrogacy #AllergyImmunology #Rashes #Hives #Hormones

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog/ If you ever wondered if there was something other than anti-cancer chemicals, quarantine or vaccines to help protect you from cancer and viral illness, there is a safe, inexpensive and effective medical treatment.  Why haven't you heard of this wonder drug?  The FDA has blocked the US population from access to this immune stimulator in the middle of a pandemic!  I can't tell you why, except that it gave us a way to improve our immune status without other preventive treatments.  It is not dangerous so you can only imagine your own reasons for this action. ‘In this blog I am going to inform you of this option so your will know about it and possibly help drop the ban on compounding pharmacies from making this communicator protein.  I have included quotes from medical and scientific journals to support my information. At the end of the blog, I will list the sources for my information in case you question my information, you can look it up! “Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying, enhancing, and restoring immune function. Thymosin alpha 1 has been utilized in the treatment of immunocompromised states and malignancies, as an enhancer of vaccine response, and as a means of curbing morbidity and mortality in sepsis and numerous infections “, World Journal of Virology 2020 Dec 15; 9: 67-78. This “bit of protein” is called a peptide, and it is just one of thousands of peptide communicators produced by the human body. When we are young and healthy these communicators are all working well in healthy mature adults, but as we age, we lose the ability to produce many of the peptides that keep us healthy, like Thymosin alpha 1. This is the reason that people over 60 get sick and die from infections that don't kill younger people. In the Journal of Virology this information was written in December of 2020, during the Covid Pandemic: Studies have postulated that thymosin alpha 1 could help improve the outcome in severely ill corona virus disease 2019 patients by repairing damage caused by overactivation of lymphocytic immunity and how thymosin alpha 1 could prevent the excessive activation of T cells. …. thymosin alpha 1 deserves further investigation into its antiviral properties and possible repurposing as a treatment against severe acute respiratory syndrome coronavirus-2. What does Thymosin Alpha 1 do? Thymosin alpha-1 (TA1) functions as a stimulator to the thymus gland.  This gland produces white blood cells including but not limited to T-Killer cells and T helper cells (CD4+/CD8+ T cells) those WBCs that kill viruses, bacteria, fungus, and cancer cells.  The thymus gland is located behind the “breastbone” and is largest when we are born and shrinks as we age.  As it gets smaller, our immunity to everything decreases which is why older people get more severe infections and take longer to heal, and why older people need stronger vaccinations than younger people to get the same effect. TA1 has many functions other than increasing the number of T cells, it also increases their killing ability and modulates the T cells, so they respond to both abnormally directed immune responses (autoimmune diseases) and stimulates the activity of T cells against infections. TA1 decreases inflammation and is effective in treating pancreatitis and Hepatitis C. Regarding viruses TA1 decreases viral replication, therefore limits both the infections, communicability, and the severity of all viral infections. For cancer patients this peptide is amazing at limiting both incidence and growth of cancers. It is unparalleled in its activity against cancer recurrence. ..thymosin alpha 1 works via two main mechanisms: Either stimulating the immune system or employing its anti-proliferative activities on tumor cells. The protective action of thymosin alpha 1 against oxidative damage because of its effect on liver superoxide dismutase and glutathione peroxidase has been explored by Armutcu et al [26]. I have given TA1 to patients who have small tumors or failure of cancer treatment, when there is no more treatment left for them, to stimulate their own immune system to kill cancer cells. There are basically 3 other ways to kill cancer.  Surgically remove it, kill it with chemicals that also kill beneficial cells in your body (chemotherapy), or radiate the area of cancer.  However mainstream medicine rarely uses the fourth most effective and least dangerous method of stimulating the natural immune system and preventing and killing cancer. One of the unused methods of killing cancer cells is prescribing TA1 which stimulates your own immune system to kill cancer cells. This fact is rarely discussed by doctors, but it is a fact that everyone produces cancer cells in their bodies daily and when they are young and healthy their own immune system kills those cancer cells. When we are young, cancer is rare because our immune cells are activated by TA1 produced in our own thymus glands.  As we age, our thymus shrinks, our TA1 decreases and some of these abnormal cells are missed and not killed, which allows these cells to grow and proliferate into what we call cancer.  The true cause of cancer is the loss of normal immunity (TA1) to kill cancer cells. Due to the action of thymosin alpha 1 on other cell types, it is used as a therapeutic agent for diseases with evident immune dysfunction [4]. Clinical trials with thymosin alpha 1 for diseases like DiGeorge syndrome, non-small cell lung cancer, hepatocellular carcinoma, hepatitis B and C, HIV, and melanoma have been conducted and yielded promising results.  FDA approved the orphan drug thymalfasin (Zadaxin) for treatment of malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma due to its immunomodulatory and anti-tumor effect. These diseases are the ones approved by the FDA for treatment with Thymosin alpha 1, in the form of the pharmaceutical called Thymalfasin, however they have ignored the elephant in the room: Thyomsin alpha 1 is effective against cancer, and preventing cancer recurrence, autoimmune diseases, viruses, parasites and bacterial infections.  Why isn't it used in the US to stimulate our own thymus to act like it did when we were younger?  I can't understand it! When we needed this compounded drug the most—in the middle of a pandemic, the FDA prevented all the compounding pharmacies from making it!  This could have been an answer for those people who could not or would not get vaccinated, but in the beginning of the pandemic, production was shut down! Thymosin alpha 1 works and there is a lot of research to back this up, but it is unattainable in the US since Covid started.  I had several patients with recurrent cancer on this peptide for years before the pandemic, and it prevented a recurrence. These patients got their medication from compounding pharmacies, and it had to be discontinued because no compounding pharmacy was allowed to make it.  Why? Both patients, who had. exhausted their mainstream medical options for their cancer, are now experiencing a recurrence of their cancer without being able to get this drug. With all this proof and knowledge about the power of Thymosin alpha1, to prevent and treat viral illnesses and cancer, why have you never heard of it, especially at a time of pandemic when this peptide could do so much good to prevent and treat the virus that is causing our pandemic, especially for those people with immune dysfunction, cancer, autoimmune diseases, and immune senescence of aging? First, the government enacted an FDA letter to all doctors threatening discipline for doctors and healthcare workers who recommended “unproven” therapies for the Covid virus. Included in this new law, rule, is to silence anyone saying to their patients that Vitamin D (which has now been proven to protect against Covid), Quercetin which has supporting evidence in the medical literature to prevent the recommendation of doctors to patients from suggesting these methods of preventing supplements to our patients. If anyone can explain why our own government is working against us (both patients and doctors who are working to save lives), and using our tax dollars to do it, please tell me. I always thought being a doctor in America meant being able to use any safe and effective means that I know works effectively, to treat my patients.  Doctors were effectively gagged by the FDA letter sent in December 2020, from telling my patients about preventive medicine practices that stimulate the immune system and protect us from infection.  Now I have lost respect for the government who treats us all like we are uneducated and sheep who will follow whatever they tell us. They use the one size fits all in a decade when the practice of medicine is becoming more aware of the individuality of patients especially in the melting pot of the US.  Drugs are ridiculously expensive and unaffordable except for the very rich.  We often use compounding pharmacies for alternatives to this price burden for patients and offer inexpensive alternatives that patients can afford.  I am listing the medical references that support my information.  I don't generally do this but I believe it is important to support my blog. References: World Journal of Virology: Thymosin alpha 1: A comprehensive review of the literature, 2020 Dec 15; 9: 67-78. Regulatory Focus, webpage, FDA Targets Remdesevir , Thymosin Alpha In Compounding ,concerns, posted Feb 24 2021 by Kari Oakes. American Journal Health System Pharmacy. May 15, 2001;58(10):878-885.

Courageous Convos is a weekly live webinar hosted by Voices For Freedom co-founders (Claire, Alia & Libby) with international guest, Dr. Geert Vanden Bossche. The former pharma, Gates Foundation, GAVI, and WHO insider spoke with us about his public concerns about the vaccine, the potential for virus mutation, and the possible consequences. Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development. Geert then moved on to join the Bill & Melinda Gates Foundation's Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness. Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech/ Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines. Geert was interviewed live on 11 October 2021. Remember to sign up to our mailing list to keep informed: www.voicesforfreedom.co.nz/stay-informed/ For more podcasts on these and other topics relating to upholding our freedoms join Claire, Libby and Alia at VOICES FOR FREEDOM - https://voicesforfreedom.co.nz

There is no exaggeration of how important stem cells are to our body, especially when it comes to healing, repairing, and making changes. In this time of COVID, we need to learn how to take care of them more so they can protect us from the virus and other diseases. Haylie Pomroy invites an expert to the show to help us understand the power they hold to our health and wellbeing. She is with Dr. Rafael Gonzalez, a Ph.D. from the University of California, who is responsible for the development of clinical stem cell applications for several disease/trauma states. Here, Dr. Gonzalez dives deep into stem cell research and therapies that can support us in our journey towards good health—from cell-based immunotherapy to growing our NK cells (natural killer cells). He talks about how putting power on your plate can change the trajectory of your health and your cells, sharing the work they are doing now to understand how these cells help you become healthier.  Love the show? Subscribe, rate, review, and share! Here's How » Join the Power On Your Plate Community today: https://hayliepomroy.com/ Pinterest Twitter Instagram Facebook YouTube

We discuss "Smart" Natural Killer Cells for Cancer Treatment, Sonny Hsiao of Acepodia. A clinical trial targeting HER2-expressing solid tumors with “smart” NK cells.   Sonny Hsiao is the founder and CEO of Acepodia. Founded in 2016 the company seeks to develop new therapies in immune-oncology and cell therapy medicine. Put another way Acepodia is a novel technology platform that serves to arm immune cells with antibodies to cure cancer. Company Website: www.acepodia.com LinkedIn: https://www.linkedin.com/in/sonny-hsiao-83199956/

This episode covers natural killer cells!

In this episode we chat to Tor Cook. She talks to us about her journey through recurrent miscarriage and IVF which has led to the current pregnancy with twins. We discuss how she coped with the rollercoaster of emotions and dealing with this while living as an ex-pat in Bermuda and we hear about her diagnosis and treatment for high NK cells. Lots of laughs. Warning: mention of butt plugs. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Thanks for listening to the podcast. Please don't forget to subscribe, rate, review and share.Contact us via social media platforms or email info@theworstgirlgangever.co.ukYou'll find us on...FacebookInstagram Twitter or you can join the ‘1 in 4' support groupIt's time to break the silence and open up the dialogue around the topics of miscarriage and pregnancy loss. No more shame, no more taboo, lets ditch it for our children; the ones that will come, the ones that are and the ones that never came to be.Proudly sponsored by Peanut - the app where you can meet like minded women who are trying to conceive. Download for free HERE or find it on your app store. 

What do the Iditarod and the immune system have in common? How can we harness the body's defenses for fighting off infections and invaders to tackle eczema and its complications, including eczema herpeticum.  Our guest for this episode of Eczema Breakthroughs is Dr. Brian Kim, Assistant Professor of Dermatology, Anesthesiology, Pathology and Immunology, and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis. His laboratory focuses on the immune mechanisms that underlie skin inflammation and the sensation of itch, and his groundbreaking translational research is showing new ways for addressing eczema by priming – rather than discouraging – the immune system.  Research referenced in this episode: https://medicine.wustl.edu/news/revving-up-immune-system-may-help-treat-eczema/ (Revving up the immune system may help treat eczema)

https://abdjuwear.com/

In the second half of this two part episode, Sarah & Kaela are once again talking about infertility in Hollywood.  This time, they're talking about infertility in movies and share some opinions on how infertile women and couples are portrayed in film today.  A few of the movies they talk about include: “Game Night,” “The Help,” and “Up!” They also share two recent documentaries, “One More Shot” and “Vegas Baby,” that capture the feelings and experiences of real people going through the struggle of infertility.  Kaela also gives an update on “The Handmaid's Tale.” She's feeling uncomfortable!   Finally, Sarah share's her doctors opinions on a few controversial fertility treatments that Kaela knows a lot about.  First, treatment of MTHFR and Folic Acid vs L-methylfolate. And second, IVIg Immunotherapy for an overactive immune system (Natural Killer cells, Cytokines, Antinuclear Antibodies, Antiphospholipid Antibodies, the list goes on…).  Find out if Kaela agrees with Sarah's doctor!   Email questions, comments, and other mafia matters to infertilemafia@gmail.com Join the closed Facebook group: The Infertile Mafia Follow on Instagram @infertilemafiapodcast